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Abstract
Background: RC-101 is a congener of the antiretroviral peptide retrocyclin, which we and others have reported is active
against clinical HIV-1 isolates from all major clades, does not hemagglutinate, and is non-toxic and non-inflammatory in
cervicovaginal cell culture. Herein, film-formulated RC-101 was assessed for its antiviral activity in vitro, safety in vivo,
retention in the cervix and vagina, and ability to remain active against HIV-1 and SHIV after intravaginal application in
macaques.
Methodology/Principal Findings: RC-101 was formulated as a quick-dissolving film (2000 mg/film), retained complete
activity in vitro as compared to unformulated peptide, and was applied intravaginally in six pigtailed macaques daily for four
days. At one and four days following the final application, the presence of RC-101 was assessed in peripheral blood,
cervicovaginal lavage, cytobrushed cervicovaginal cells, and biopsied cervical and vaginal tissues by quantitative western
blots. One day following the last film application, cervical biopsies from RC-101-exposed and placebo-controlled macaques
were collected and were subjected to challenge with RT-SHIV in an ex vivo organ culture model. RC-101 peptide was
detected primarily in the cytobrush and biopsied cervical and vaginal tissues, with little to no peptide detected in lavage
samples, suggesting that the peptide was associated with the cervicovaginal epithelia. RC-101 remained in the tissues and
cytobrush samples up to four days post-application, yet was not detected in any sera or plasma samples. RC-101, extracted
from cytobrushes obtained one day post-application, remained active against HIV-1 BaL. Importantly, cervical biopsies from
RC-101-treated animals reduced RT-SHIV replication in ex vivo organ culture as compared to placebo-treated animals.
Conclusions/Significance: Formulated RC-101 was stable in vivo and was retained in the mucosa. The presence of antivirally
active RC-101 after five days in vivo suggests that RC-101 would be an important molecule to develop further as a topical
microbicide to prevent HIV-1 transmission.
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Introduction
Mucosal surfaces are the portals for sexual transmission of HIV-1 and
therefore play a major role in the pathogenesis of primary infection.
Antimicrobial peptides are effector molecules that constitute the first line
of host defense at mucosal surfaces. Human cervicovaginal mucosa
expresses a number of peptides that are intrinsically active against
bacteria, fungi, and viruses such as HIV-1. However, despite their
protectivefunction, which likely contributes to the low incidence of HIV-
1 transmission in women (approximately 3 in 1000 coital acts; [1,2]), the
barrier is not complete and therefore exogenously administered
preventatives are necessary to reduce the incidence of HIV-1 infection.
Retrocyclins are cationic, b-sheet, 18-residue peptides, which are
stable and can resist boiling, acidic conditions, and other harsh
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15111environments. Our group first reported that the rhesus homologs of
retrocyclins prevent infection by both X4- and R5-strains of HIV-1
in cell culture [3]. However, whereas other antimicrobial peptides
areproducedbybothhumanand non-humanprimates[4],humans
donotnaturallyproduceretrocyclinsduetoapremature stop codon
that prevents translation [3,5]. The remainder of the retrocyclin
gene is remarkably intact, and thus we used the genetic information
contained therein to recreate retrocyclin synthetically [3]. We
determined that retrocyclin potently protectedprimary PBMCs and
CD4
+-enriched T cells from in vitro infection by both X4 and R5
strains of HIV-1 [3], and exhibited much greater activity than other
human antimicrobial peptides tested [6].
From a screen of over 120 synthetic analogs of retrocyclin, we
identified one called ‘‘RC-101’’ that exhibited a number of beneficial
properties that indicate suitability for further development as a topical
microbicide.RC-101inhibitedtheformationofHIV-1proviralDNA
[3,7], and exhibited broad activity against many clinical isolates of
HIV-1 from all major subtypes [8,9]. Retrocyclins such as RC-101
prevent HIV-1 entry by binding to the heptad repeat 2 (HR2) region
of HIV-1 gp41, which precludes six-helix bundle (6HB) formation
and subsequent viral fusion [10–12]. Furthermore, RC-101 effec-
tively inhibits HIV-1 infection of organotypic cervicovaginal tissues
without inducing toxicity or inflammation [7], and induces only
m i n i m a lr e s i s t a n c ei nH I V - 1t h a tc a nb eo v e r c o m ew i t hs l i g h t
increases in peptide concentration [10]. Together, these properties
suggest that RC-101 would be an ideal molecule to develop as a
topical microbicide to prevent HIV-1 transmission.
An ideal topical microbicide product should be effective in
preventing HIV infections while not irritating the mucosal surface
or adversely affecting normal flora of the vagina after chronic
usage. In order to protect oneself during each sexual encounter,
women will require repeat applications of the microbicidal
formulation. For this reason it is imperative that studies of
multiple perturbations with candidate microbicides be performed.
Because clinical trials are too cumbersome and expensive for
screening purposes, animal models are desirable. The pigtailed
macaque model is a well-established system to evaluate microbi-
cide agents as it has several advantages over small animals [13,14].
The reproductive tract of the pigtailed macaque is similar to that
of the human: it has regular menstrual cycles of 28 to 30 days and
exhibits typical hormonal and genital tract changes as compared
to women. Moreover, the vaginal flora is remarkably similar to the
human, including the presence of endogenous lactobacilli, and in
particular the beneficial H2O2-producing lactobacilli [15,16]. The
pigtailed macaque model has been used to evaluate several
microbicidal compounds to determine whether repeated use of
these compounds would have deleterious effects on the vaginal
environment [13,14,17–22]. Given these beneficial metrics in
assessing topical microbicide safety, we chose to utilize the
pigtailed macaque model to evaluate RC-101 in vivo [23].
In this report, we evaluated a quick-dissolving film of RC-101
applied daily for four days to pigtailed macaques, for its safety in
vivo, bioavailability, and antiviral activity. Our data indicate that
film-formulated RC-101 was safe and retained in the cervical and
vaginal tissues. Importantly, cervical biopsies from RC-101-
instilled animals reduced RT-SHIV replication in an ex vivo organ
culture model.
Results and Discussion
Activity of formulated RC-101 is equivalent to
unformulated peptide
We previously reported that unformulated RC-101 was active
against multiple clinical isolates of HIV-1 from all subtypes, and
was neither toxic nor proinflammatory to cervicovaginal cells or
tissues both in vitro and ex vivo [7]. In the current study, we
evaluated RC-101 that was formulated in a quick-dissolving film
suitable for in vivo intravaginal delivery in pigtailed macaques. We
first assessed whether RC-101 retained antiviral activity following
formulation. Film-formulated RC-101 (2000 mg/film) and placebo
control films both rapidly dissolved in culture media (,5 min),
and upon dissolution completely released RC-101 into the media
as measured by quantitative immuno-dotblots (data not shown).
RC-101 and placebo films were then evaluated in vitro against the
R5-tropic HIV-1 strain BaL in TZM-bl reporter assays
(Figure 1A; n=5), which quantified infection as a measure of
Tat-driven luciferase production, and PM1 assays (Figure 1B;
n=3–5), which measured infection by quantifying viral p24
gag
antigen release in the supernatants of these lymphocytic cells. In
both assays, film-formulated RC-101 exhibited potent antiviral
activity, which was equivalent to unformulated RC-101 tested at
the same concentration. At 5–10 mg/ml, film-formulated RC-101
inhibited more than 90% of HIV-1 replication. Interestingly,
placebo films exhibited modest anti-HIV-1 activity in both assays.
Similarly, by measuring p24 release in culture supernatant, the
activity of RC-101 films was significantly higher at days 5 and 7
than unformulated RC-101 (Figure 1B; n=2-5; P,0.001 and
P=0.019, respectively). Collectively, these results suggest that film-
formulated RC-101 retained its potent antiviral activity. Further-
more, excipients within the films do not adversely affect antiviral
activity, and instead might serve to augment antiviral activity of
RC-101.
RC-101 was safe and well tolerated when applied
intravaginally in pigtailed macaques
Evaluation of safety of RC-101 was conducted in vivo in a
pigtailed macaque model using films that each contained 2000 mg
RC-101. This dose was selected for two reasons: First, evaluation
of safety of a product in vivo should be conducted at higher doses to
identify more accurately any toxic effects of the product. Second, it
is likely that doses required for efficacy in vivo are several fold
higher than doses required for efficacy in vitro. Indeed, the dose
chosen for the in vivo studies herein was 1000 times higher than the
IC50 of RC-101 in vitro [8].
In vivo safety evaluations were conducted as described in
Figure 2, and colposcopy, pH and vaginal microflora determi-
nations were the parameters used to evaluate safety of RC-101
films. The colposcopy of the cervix of representative animals
before RC-101 or placebo film insertion, at the time of insertion,
and 30 min and 24 hr after film insertion is shown in Figure 3.
The film was gelatinous by 30 minutes and by 24 hrs complete
disintegration of the film was observed. No visual changes were
seen in the cervix following RC-101 or placebo film exposure. The
visual observation was repeated after each film application (total of
four films per animal over four consecutive days) and no visual
changes were observed in any of the colposcopic evaluations,
suggesting RC-101 was safe.
Vaginal pH was monitored 30 min after each film application
and at days 5 and 8 after the last film application (Figure 4A and
4B). No significant changes in pH were observed after application
of RC-101 films, with the pH remaining within the normal range
of macaque vaginal pH for all films tested. Interestingly, thirty
minutes following application at Day 4, placebo films reduced
vaginal pH as compared to RC-101 films (Figure 4B; P=0.003).
The finding that RC-101 films did not alter vaginal pH at any time
point exemplifies the safety of this formulated compound. Vaginal
microflora examined showed detection of H2O2-producing
Lactobacilli spp.,H 2O2-producing Viridians spp., Staphylococcus aureus,
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microorganisms (not shown). For 19 microorganisms, no discern-
ible differences were found between the RC-101 films and placebo
films. There appeared to be a trend towards several RC-101-
exposed monkeys having the presence of S. aureus towards the end
of the study. In total, microbiological evaluation of vaginal
microflora after application of RC-101 and placebo films (days 1
to 4 during film application; and, followup days 5 and 8) suggest
that RC-101 had minimal effects on the microbiota of the vaginal
vault. Likewise, assessment for the presence of neutrophils from
Gram-stained wet mounts revealed no appreciable difference
between RC-101 and placebo films (not shown). These collective
findings underscore the safety of RC-101 when applied intravag-
inally in pigtailed macaques.
RC-101 was retained in the cervicovagina up to four days
post-application
We next assessed for the presence of RC-101 in cytobrushes,
serum, plasma, and biopsies from both the cervix and vagina at
days 5 and 8, as well as cervicovaginal lavage (CVL) fluid at day 8
(Figure 5). Each sample was extracted in 10% acetic acid to
liberate RC-101, and the clarified extracts were lyophilized,
resuspended in 0.1% acetic acid, and subjected to quantitative
anti-RC-101 western blot analyses using synthetic unformulated
RC-101 as the standard (Figure 5B). RC-101 was present at the
highest concentrations in day 5 cytobrushes from all but one RC-
101-treated monkeys, with four monkeys’ cytobrushes still
containing RC-101 at day 8 (Figure 5A). Considering how few
cells are routinely recovered using the cytobrush technique, the
amounts of RC-101 retained in the vaginal mucosa in vivo would
therefore be expected to be quite high. Notably, for cytobrush
samples, the concentration of RC-101 was directly proportional to
the amount of protein within a given sample (data not shown),
suggesting that the differences observed between samples may be
attributed in part to variability in the number of cells retrieved by
brushing. At day 5, RC-101 was also present in both cervical
biopsies and one of two vaginal biopsies; however, due to the small
size of the pinch biopsies, the amount of RC-101 recovered was
near the limit of detection. CVL fluid in general contained low
amounts of RC-101, further implying that RC-101 might be
retained on or within the cervicovaginal epithelia. RC-101 was not
detected in plasma or serum from any RC-101-treated animal, nor
was RC-101 detected in any of the placebo cytobrush, biopsy,
serum, plasma, or CVL samples. The finding that RC-101 was
Figure 1. Activity of formulated RC-101 is equivalent to unformulated peptide. Antiviral activities of RC-101-containing films and placebo
films against HIV-1 strain BaL were compared against unformulated ‘‘pure’’ RC-101 peptide in TZM-bl reporter assays expressed as percent inhibition
of HIV-1 infection (A) and p24
gag release assay in PM1 cells expressed in pg/ml of p24 released (B). p24
gag differed between formulated and
unformulated RC-101 at days 5 and 7, P,0.001 and P=0.019, respectively. Error bars represent SEM; n=2-5.
doi:10.1371/journal.pone.0015111.g001
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concentrations even four days after the last film application was
remarkable when one considers its prolonged contact with the
cervicovaginal mucosa. RC-101 may thus be suitable as a topical
microbicide wherein the product could be used prophylatically in
a manner dissociated from coitus.
Figure 2. In vivo study protocol in pigtailed macaques. (A) Two studies were performed. The first included five macaques, in which each
monkey received placebo films followed six weeks later with RC-101 films. The second study included the five original macaques plus an additional
monkey, in which half received RC-101 films and half received placebo films. Six weeks later, each monkey receiving the opposite film type. (B)
Baseline measurements for colposcopy, vaginal pH, and microflora were obtained at day 0. At days 1–4, RC-101- or placebo-containing films were
instilled intravaginally. At days 5 and 8, cytobrushes, blood, and pinch biopsies were obtained, and at day 8 CVL fluids were obtained from each
monkey.
doi:10.1371/journal.pone.0015111.g002
Figure 3. Colposcopy of the cervicovagina reveals no adverse effects of RC-101 films. Images from colposcopic examination of
cervicovaginal mucosa of a representative pigtailed macaque obtained prior to film insertion, at the time of insertion (Time 0), and 30 min and 24 hr
after film insertion. Note the absence of mucosal aberrations at all time points with either RC-101 films or placebo films.
doi:10.1371/journal.pone.0015111.g003
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active against HIV-1 and SHIV
To determine the bioavailability of RC-101 in the cervicovag-
inal environment after prolonged exposure, cytobrush samples
were extracted and assessed for antiretroviral activity against HIV-
1. RC-101 was extracted from day 5 cytobrushes (n=3) using 10%
acetic acid, and RC-101 concentration was determined by
quantitative western analyses. Extracted RC-101 was assayed for
anti-HIV-1 activity against HIV-1 strain BaL in TZM-bl cells
(Figure 6A). Extracted film-formulated RC-101 exhibited antivi-
ral activity in a dose response manner with the highest activity at
10 mg/ml.
Cervical tissues, exposed to film-formulated RC-101, are
resistant to ex vivo RT-SHIV challenge
In a final test for efficacy, we obtained four macaque cervical
biopsies, two each from RC-101-treated and placebo-treated
animals, and challenged each biopsy with RT-SHIV for 24 hrs in
an organ culture. Viral replication was monitored by measuring
infectious virus in TZM-bl cells. Figure 6B reveals that biopsies
obtained from RC-101-treated macaques produced substantially
less virus than biopsies from placebo-treated animals. Taken
together, our data demonstrate that RC-101 was retained in the
cervicovaginal mucosa in its active form for extended periods of
time, further bolstering the utility of RC-101 as a topical
microbicide. Moreover, our data indicate that in vivo administra-
tion of a topical microbicide followed by ex vivo viral challenge in
both cell and tissue cultures is a highly useful approach to assess
the effectiveness of microbicide candidates prior to expensive in vivo
efficacy studies in nonhuman primates.
One of the unique features of this study lies in the plan to
characterize and develop an ancestral human antimicrobial
peptide into a topical microbicide to prevent HIV-1 infection.
Phylogenetic evidence from our group indicates that human
retrocyclins were silenced after the orangutan and hominid
lineages had diverged [5]. Given that retrocyclin is an effective
inhibitor of HIV-1 infection, the evolutionary loss of retrocyclin
Figure 4. RC-101 films do not alter vaginal pH or microbiological profile of the cervicovagina. (A) Vaginal pH was measured prior to film
instillation at days 1-4 (D1-D4) and at followup (D5 and D8). Each measurement represents one experimental condition in a pigtailed macaque.
Horizontal lines represent the mean value for all 11 replicates. No differences were observed between monkeys that were receiving RC-101 films or
placebo films. (B) represents the difference in vaginal pH between the time zero condition and 30 minutes after film instillation for each day films
were applied (D1–D4). Horizontal lines represent the mean value for all 11 replicates. A significant difference was observed at Day 4 (P=0.003), with
the placebo films inducing a greater change in vaginal pH than the RC-101 films. (C) Four (of twenty) microbes are presented for both RC-101 films
and placebo films. For each microbe, there are 10 vertical bars, representing the number of replicates (from a total of 11) that were positive for the
microbe indicated. The ten bars for each microbe signify the following from left to right: Day 1 (D1) time zero (t0), D1, time 30 min (t30), D2 t0, D2
t30, D3 t0, D3 t30, D4 t0, D4 t30, D5 and D8.
doi:10.1371/journal.pone.0015111.g004
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If so, then the topical administration of retrocyclins, such as RC-
101, to humans would restore natural effector molecules that were
never relinquished by many of our nonhuman primate relatives.
Not only might the use of a human-derived peptide reduce the
toxicity and allergy that can be associated with chemically
synthesized compounds or non-mammalian peptides, to our
knowledge HIV has not encountered retrocyclin ‘‘in the wild’’
and thus far should not have developed resistance. Indeed, RC-
101 itself induces little resistance in HIV-1 [10], further
underscoring its potential as a topical microbicide.
In summary, based on low toxicity, good bioavailability in the
cervix and vagina, and in vitro and ex vivo challenge data, RC-101
appears to be a promising compound suitable for further
development as a topical vaginal microbicide to prevent sexual
transmission of HIV-1.
Materials and Methods
Ethics statement for in vivo evaluations in pigtailed
macaques
A total of six sexually mature female Macaca nemestrina were
obtained from a colony of animals at the Washington National
Primate Research Center. Prior approval for use of monkeys in
this protocol was obtained from the Institutional Animal Care and
Use Committee at the University of Washington. Animals were
handled humanely, and experiments were performed within the
National Institutes of Health’s laboratory animal use guidelines.
Figure 5. RC-101 was retained in the cervicovagina up to four days post-application. RC-101 was assessed by quantitative western blot
from acetic acid-extracted samples of cervical biopsies, vaginal biopsies and cytobrushes at day 5, and cytobrushes and CVL fluid at day 8 (A). Note
that CVL fluid was subdivided into both the cellular portion and the fluid portion. A representative western blot for RC-101 in cytobrushes at day 5 is
shown in (B), with ‘‘M1’’, ‘‘M2’’, and ‘‘M3’’ signifying three individual monkeys. Note that the same monkey received both RC-101 films and placebo
films six weeks apart, and that RC-101 was absent in cytobrushes obtained from monkeys that received placebo films. The P-values presented were
adjusted for multiple comparisons using Tukey method.
doi:10.1371/journal.pone.0015111.g005
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Two studies were performed as delineated in Figure 2A. Films
were applied to the animals following the experimental design in
the schema shown in Figure 2B. Films of RC-101 2000 mg/film
were assessed for safety with vaginal application and compared to
a placebo film. Each animal controlled for itself by completing
both arms of the study (first RC-101 and then placebo film). For
each study, each animal received one film/day for a period of 4
days. On study days 1 to 4, colposcopy assessments, and swabs for
vaginal pH, neutrophil quantification, and microflora were
obtained at time zero. Immediately following specimen collections,
an intravaginal application of 1 film (RC-101 or placebo) was
administered to each animal. Colposcopy and vaginal swabs were
again performed 30 min after film application. Colposcopy was
conducted every day after 30 min of application and before the
next day application. On study days 5 and 8, colposcopy, and
swabs for vaginal pH, neutrophils and microflora were collected to
document recovery. Standardized colposcopic assessments were
conducted by a team of three cross-trained individuals. In order to
document the appearance of the cervicovaginal tissues prior to
potential tissue perturbation caused by sampling, colposcopy took
place immediately after speculum placement before any swab
collections. Vaginal pH was determined by rolling a swab of
vaginal secretions onto a pH indicator strip with a resolution of 0.5
pH unit. A second vaginal swab was collected and immersed in a
transport tube (Port-a-Cul; Becton Dickinson Microbiology
Systems, Cockeysville, MD) for semi-quantitative microbiologic
characterization. Microbiologic characterization was conducted in
the laboratory of Sharon Hillier, Ph.D. (Magee Womens Research
Institute, Pittsburgh, PA). Neutrophils were quantified through
enumeration of Gram-stained vaginal wet mounts as described
previously [24]. In addition, cytobrushes, serum, plasma, and
pinch biopsies at days 5 and 8 and cervicovaginal lavage at day 8
were collected, and sent to the University of Central Florida for
evaluation of RC-101 concentration and anti-HIV-1 activity.
Cervical biopsies were also sent to the University of Pittsburgh for
ex vivo analyses of anti-SHIV activity. Notably, for the second study
(Figure 2A), samples were sent to investigators at the University of
Central Florida and the University of Pittsburgh in a blinded
fashion.
Extraction of RC-101 from macaque samples
Macaque samples (cervix/vagina biopsy, cytobrush, CVL,
serum, or plasma) were harvested at the University of Washington,
shipped on dry ice, and stored at 280uC. To extract RC-101,
samples were mixed with glacial acetic acid to a final
concentration of 10% (v/v), vortexed for 20 min at RT, and
centrifuged at 13,000 rpm for 10 min at 4uC. Supernatant
containing acid-soluble RC-101 was collected, and insoluble
material was re-extracted with 5 volumes of 10% acetic acid for
another 20 min. Following centrifugation, the supernatants were
pooled, vacuum concentrated, resuspended to their original
volume with 0.1% acetic acid/molecular grade water (v/v), and
stored at 280uC prior to immuno-detection.
RC-101 synthesis, processing, purification, and
formulation as intravaginal films
The 18 amino acid RC-101 peptide was prepared on a
0.25 mmol scale with an ABI 431A peptide synthesizer using
FastMoc
TM chemistry [25] as described in [3]. In brief, Fmoc-
Wang resin (100-200 mesh) was used to synthesize the reduced
monomer (Novabiochem, San Diego, CA) and all residues were
double coupled to insure optimal product yield. After cleavage and
deprotection of the peptide from the resin using trifluoroacetic
acid:1,2-ethanedithiol: thioanisole:water, 10:0.25:0.5:0.5 (v:v), the
linear reduced RC-101 was separated from the resin by filtration
and precipitated from solution with tertiary butyl ether and
purified by preparative scale reversed-phase (RP)-HPLC using a
Vydac C18 column. The purified reduced RC-101 was oxidized
with 10 mM ammonium acetate buffer pH 7.5 for 18 hrs by
stirring at 25uC, followed by vacuum-concentration and separa-
tion of the oxidized from unreacted peptide with RP-HPLC [3].
Oxidized RC-101 was cyclized by dissolving at a concentration of
0.5 mg/ml in DMSO that contained 60 moles of EDC (1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide) and 20 moles of HOBt (N-
hydroxbenzotriazole) per mole of RC-101 and stirred in the dark
at 20uC for 18 hrs. The solution was concentrated at 80uC and the
derivative separated from non-cyclized material by RP-HPLC.
After each processing step, peptides were subjected to MALDI-
TOF mass spectrometry to confirm homogeneity and that the
measured mass agrees well with its expected mass. RC-101 was
formulated by solvent casting techniques as a quick-dissolving
polymeric 27.5 mm633.5 mm vaginal film, composed of 2000 mg
RC-101, 6% polyvinyl alcohol (Kuraray America Inc., New York,
NY), 0.12% hydroxypropyl methylcellulose 6 cps (HPMC) (Sigma,
St. Louis, MO), and 3% glycerin (Dow Chemical Co., Midland,
MI) as described in Sassi and colleagues [26]. All films were stored
Figure 6. Presence of RC-101 in cytobrush samples from cervix
and its antiviral activity in vitro and ex vivo. (A) Acetic acid-
extracted day 5 cytobrush samples from three monkeys were assayed
against HIV-1 strain BaL in a TZM-bl reporter assay, and compared to
unformulated ‘‘pure’’ RC-101. No statistical differences were observed
between extracted and pure RC-101 samples. (B) RT-SHIV replication in
tissues from monkeys exposed to film formulated RC-101 or placebo
film in an organ culture. The amount of virus in culture supernatant was
quantified in a TZM-bl assay. Means of two tissues per condition are
given.
doi:10.1371/journal.pone.0015111.g006
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Inc., Mundelein, IL) until used for subsequent analyses.
Cells and Virus
The following reagents were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH: TZM-bl cells from Dr. John C. Kappes, Dr. Xiaoyun
Wu and Tranzyme Inc. [27–30], PM1 cells from Dr. Marvin Reitz
[31], and HIV-1 Ba-L from Dr. Suzanne Gartner, Dr. Mikulas
Popovic, and Dr. Robert Gallo [32]. TZM-bl is a HeLa cell line
stably expressing large amounts of CD4 and CCR5 and has
luciferase and B-galactosidase genes under control of the HIV-1
promoter. TZM-blcells weremaintainedwithDMEM high glucose
(Mediatech, Inc., Manassas, VA) containing 100 U/mL penicillin/
0.1 mg/mL streptomycin (Mediatech) and 10% (v/v) heat-
inactivated FBS (Gemini Bio-Products, West Sacramento, CA).
PM1 cells readily propagate R5 and X4 HIV-1. They were
maintained at 0.4–0.8610
6/mL in RPMI 1640 (Mediatech)
containing 10 mM HEPES, 100 U/mL penicillin/0.1 mg/mL
streptomycin, and 20%(v/v) FBS. HIV-1 BaL stocks were prepared
by infecting 3610
6 PM1 cells for 3 hr, washing the cells of excess
virus, and growing the cells at 0.75610
6/mL. Cell supernatants
containing propagated virus were collected every other day starting
at day 3 post-infection. Supernatants were clarified by centrifuga-
tion, filtered through at 0.45 uM nylon syringe filter, and stored at
280uC in aliquots for use as virus stocks. These HIV-1 BaL viral
stocks were quantified using an HIV-1 p24 ELISA (Perkin Elmer,
Freemont, CA), and virus titers (TCID50/mL) were determined by
titration on TZM-bl and PM1 cells.
Antiviral Assays
Placebo films and films formulated with 2000 mg RC-101 were
dissolved in warm growth media so that the final presumptive
concentrations administered to cells were 1.25–20 mg/mL peptide.
As an initial screen for anti-viral activity, TZM-bl reporter cells
were seeded at 4000 cells/well in 96W black plates (Corning,
Lowell, MA) and infected the next day with 800 TCID50/mL
(MOI=0.02) HIV-1 BaL in the presence of 1.25–20 mg/mL of
pure RC-101 peptide (or the equivalent amounts of 0.01% acetic
acid vehicle) or the above mentioned dilutions of placebo versus
RC-101 formulated films. After 24 hr, supernatants were removed
and cells were lysed with 100 uL of 1X Glo Lysis buffer (Promega
Corp., Madison, WI) and then frozen. Bright Glo luciferase assay
buffer (Promega) was then added directly to the thawed lysates and
luciferase activity was measured on an LMax luminometer
(Molecular Devices, Sunnyvale, CA). Results were confirmed
using a PM1 cell infection assay that measures propagation of
HIV-1 over 7 days. Cells (1610
5/0.1 mL) were infected with
HIV-1 BaL (1600 TCID50/0.1 mL, MOI=0.02) for 3 hr in the
presence of pure RC-101 or diluted films, then washed of excess
virus, and left to incubate (37uC/5% CO2) in 0.5 mL growth
media containing peptide or diluted films. On day 3 post-infection,
the supernatants were collected, filtered and frozen, and the cells
were resuspended in 1 mL fresh growth medium containing pure
peptide or diluted placebo versus film-formulated RC-101 for two
more days. On day 5 post-infection, this step was repeated. PM1
cell infection was quantified by performing HIV-1 p24 ELISA on
supernatants from days 3, 5, and 7.
Gel electrophoresis and semiquantitative western blot
analysis
Standards and samples were prepared in 0.1% acetic acid
containing 0.1% cetyltrimethyl ammonium bromide (CETAB)
and then admixed 1:1 with AU loading dye (9M urea in 5% acetic
acid, colored with methyl green). A 12.5% native acid-urea (AU)
PAGE was used to separate proteins based on their net charge
density, and gels were electroblotted to PVDF in ice cold 0.7%
acetic acid/10% methanol for 22 min at 180 mA as described
previously (Valore EV et al. JCI 101, 1998, and Cole AM, JI 169,
2002). Membranes were fixed with 0.1% glutaraldehyde diluted in
Tris-buffered saline (TBS, 20 mM Tris pH 7.5, 500 mM NaCl),
blocked with Superblock (Pierce, Rockford, IL) containing 0.05%
Tween20 for 30 min at 37uC with gentle agitation, and incubated
on a rocker overnight with anti-RC-101 rabbit polyclonal antisera
diluted 1:1000 in 1:3 Superblock (1 part Superblock, 2 parts TBS/
0.05% Tween20). Membranes were then washed thrice with low
salt TBS (20 mM Tris, 0.9% NaCl, pH 4.5) containing 0.1% BSA
and 0.1% Tween20, blocked with Superblock for 15 min at 37uC,
and incubated for 1 hr with goat anti-rabbit IgG-HRP (Pierce)
diluted 1:10000 in 1:3 Superblock. Following three more washes
with TBS/BSA/Tween20 and 2 washes with TBS/Tween20,
blots were developed with ChemiGlow (Cell Biosciences,Inc.,
Santa Clara, CA) and images were documented and analyzed with
Bio-Rad’s ChemiDoc XRS system and QuantityOne software
(Bio-Rad, Hercules, CA).
SHIV challenge of biopsies from pigtailed macaques
treated with RC-101 films
Monkey cervical issues, obtained at baseline and after treatment
with film formulated RC-101, were sent on cold packs in culture
medium overnight from the University of Washington, Seattle to the
University of Pittsburgh. Tissues were rinsed with an antibiotic wash
(100 units/mlpenicillin/streptomycin, nystatin, amphotericin B), and
stimulated overnight with PHA (5 mg/ml). Next day, tissues were
washed with PBS, placed in a 96 well plate and infected with 250 ml
(TCID 50) of RT-SHIV (NIH AIDS Research and Reference
Reagent Program) overnight at 37uC. Following infection the tissues
were washed three times with PBS and placed in a 48 well plate on
surgifoam (Absorbable Gelatin Sponge, Johnson & Johnson) that was
pre-soaked in RPMI 1640 containing IL-2, penicillin/streptomycin
and 20% FBS. Five hundred microliter of the same media was added
to the wells to keep biopsies in an air-liquid interface. One hundred
microliter samples were collected every 2–3 days and frozen at
280uC until testing. The samples were tested for infectivity in
indicator TZM-bl cells using luminescence (BetaGlo Assay System,
Promega). Tissue viability was tested by an MTT assay at day 20 and
all tissues were found to be viable.
Statistical analyses
Data are presented as scattergrams with mean bars which show
all data points and the group measure of central tendency. If data
weremeasured repeatedly acrosstime or dose the group meanswith
standard error bars wereplotted with lines connecting groups across
the scale the measurements were observed. The comparisons of
means between two groups (e.g., formulated versus unformulated
RC-101) were conducted using the two-sample t-test with unequal
variances. The comparisons of means among more than two groups
were conducted using the analysis of variance method. Subsequent
pair-wise comparisons (two group comparisons) were calculated to
be adjusted for multiple comparisons using the Tukey method (e.g.,
comparison of RC-101 CVL to placebo CVL at day 8 after the
comparison of treatment groups at day 8).
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